Rheumatoid arthritis (RA)
Clifton Bingham, MD
Johns Hopkins University
Baltimore, MD, United States
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing); Janssen: Consultant (Ongoing); Pfizer: Consultant (Ongoing); Sanofi: Consultant (Ongoing)
Vivian Bykerk, MD, FRCPC (she/her/hers)
Hospital for Special Surgery
New York, NY, United States
Disclosure(s): AbbVie/Abbott: Consultant (Terminated, December 1, 2022); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)
Liana Fraenkel, MD, MPH
Berkshire Medical Center
Lenox, MA, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
This Meet the Panel session will focus on the use of steroids in rheumatoid arthritis.
Panelist: Clifton Bingham, MD – Johns Hopkins University
Panelist: Vivian Bykerk, MD, FRCPC (she/her/hers) – Hospital for Special Surgery
Panelist: Liana Fraenkel, MD, MPH – Berkshire Medical Center